Nexstim Receives an NBS System Order from a Customer in Europe
Nexstim Receives an NBS System Order from a Customer in Europe
Press release, Helsinki, 25August 2022 at 10AM (EET)
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an NBS 5 System order from a customer in Europe. The customer is a new user of the Nexstim NBS system, acquiring the system to enable future neuroscience projects.
Nexstim’s SmartFocus® nTMS (navigated transcranial magnetic stimulation) technology enables accurate and personalized stimulation, considering the unique shape and conductivity of each patient’s brain. Nexstim’s NBS (Navigated Brain Stimulation) system is used, for example, in planning neurosurgery and in the case of this customer enables neuroscience studies where the stimulation needs to be targeted individually to the brain, reproducing the pulse delivery reliably for diagnosis.
This specific NBS system also includes the software of an NBT® (Navigated Brain Therapy) system, allowing it to also be used for the treatment of major depression and chronic neuropathic pain.
Mikko Karvinen, CEO of Nexstim, comments: “Nexstim has been actively working as a partner in TMS-EEG development. TMS-evoked EEG responses are sensitive to even the smallest shifts in stimulation location. While allowing highly location-specific data to be gathered, this also makes a reliable, precise and accurate navigation solution imperative for TMS-EEG measurements and even more so when studies require repeatability and reproducibility.We are very happy to see that our development work at Nexstim results in enabling new customers to use our world-leading technology in their neuroscience research projects.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bombardier Reports Significant Backlog Growth on 1.6 Unit Book-to-Bill, Expanded Margins and Service Revenues Increase in First Quarter of 202425.4.2024 12:30:00 CEST | Press release
Revenues of $1.3 billion for the first quarter reflect 13% year-over-year aftermarket growth and 20 aircraft deliveries, in line with production plan and full year delivery guidance of 150 to 155 aircraft.Adjusted EBITDA(1) of $205 million for the first quarter. Adjusted EBITDA margin(2) rose 140 bps year-over-year to 16%. Reported EBIT for the first quarter was $144 million. Adjusted EPS(2) positive at $0.36 for the first quarter, with diluted EPS(3) at $1.02. Free cash flow usage(1) of $387 million reflects expected working capital build in inventories supporting production ramp-up. Reported cash flow usage from operating activities and net additions to PP&E and intangible assets were at $343 million and $44 million respectively.Focus on deleveraging continued with $100 million debt redemption announced on March 14th and closed in April; available liquidity(1) remained strong at $1.4 billion. Cash and cash equivalents were $1.2 billion as at March 31, 2024. First quarter unit order
Resolutions of Huhtamäki Oyj’s Annual General Meeting of Shareholders25.4.2024 12:30:00 CEST | Press release
HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 25.4.2024 AT 13:30 EEST Resolutions of Huhtamäki Oyj’s Annual General Meeting of Shareholders Huhtamäki Oyj’s Annual General Meeting of Shareholders was held in Helsinki on April 25, 2024. The meeting adopted the Annual Accounts including the Consolidated Annual Accounts for 2023, discharged the members of the Company’s Board of Directors and the CEO from liability, and approved all proposals made to the Annual General Meeting by the Board of Directors and the Shareholders’ Nomination Board. The Annual General Meeting also approved the Remuneration Report for the Company’s Governing Bodies presented to it. Dividend The Annual General Meeting resolved that an aggregate dividend of EUR 1.05 per share be paid based on the balance sheet adopted for the financial period ended on December 31, 2023. The dividend will be paid in two instalments. The first dividend instalment, EUR 0.53 per share, will be paid to shareholders registered in the Company’s regis
AS Tallink Grupp Investor Webinar introducing the results of the Q1 202425.4.2024 12:30:00 CEST | Press release
On 25 April 2024 AS Tallink Grupp held an investor webinar where Paavo Nõgene, the Chairman of the Management Board, and Harri Hanschmidt and Margus Schults, the members of the Management Board introduced the results of the first quarter of 2024. AS Tallink Grupp would like to thank all the participants. The webinar presentation is enclosed and the webinar recording is available at www.tallink.com/investors/webinars. Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn, Estonia E-mail anneli.simm@tallink.ee Attachment AS Tallink Grupp Q1 2024 Webinar Presentation
Passing of Columbus A/S’ Annual General Meeting and subsequent constitution of the Board of Directors25.4.2024 12:21:35 CEST | Press release
Company announcement no. 12/2024 At Columbus A/S’ Annual General Meeting held on 25 April 2024, all proposals set out in the agenda were adopted, including the following; 1. The General Meeting took note of the Board of Directors’ report. 2. The Annual Report for 2023 was approved. 3. The Board of Directors’ proposal regarding distribution of profit was adopted, including payment of an ordinary dividend to the shareholders of DKK 0.125 per share of DKK 1.25 (nom), amounting to a total dividend of DKK 16,159,533. 4. The Remuneration Report for 2023 was approved in the indicative ballot. 5. The General Meeting authorized the Board of Directors for a period of 18 months from the date of the General Meeting to acquire up to 10 per cent of the Company’s share capital against payment which shall not deviate more than 10 per cent up or downwards from the latest listed price of the shares at Nasdaq Copenhagen prior to the acquisition. 6. Ib Kunøe, Peter Skov Hansen, Sven Madsen, Karina Kirk an
Nexstim Plc: Managers’ Transactions, Hildén25.4.2024 12:15:00 CEST | Press release
Company Announcement, Helsinki, 25 April 2024 at 1:15 PM (EEST) Nexstim Plc: Managers’ Transactions, Hildén Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to the notification requirement Name: Timo Hildén Position: Member of the Board/Deputy member Issuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 59502/4/4 ____________________________________________ Transaction date: 2024-04-23 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: 2024H Nature of transaction: ACCEPTANCE OF A STOCK OPTION (X) Linked to stock option programme Transaction details (1): Volume: 8500 Unit price: 0 EUR Aggregated transactions (1): Volume: 8500 Volume weighted average price: 0 EUR Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 50 326 4101 mikko.karvinen@nexstim.com